Could GLP-1 Receptor Agonists Be Useful in ME/CFS?

Exploring new therapeutic pathways with cautious optimism - By Buonsenso and the Kids

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) remains one of the most challenging neuroimmune diseases for clinicians, researchers, and patients alike. With limited evidence-based treatments and a pathophysiology still being pieced together, there’s growing interest in repurposing medications used in other chronic or metabolic conditions.

One surprising candidate?
GLP-1 receptor agonists — medications commonly used for type 2 diabetes and obesity — are starting to spark interest in ME/CFS research circles.